Business Context and Reporting Period
Company: AYTU BIOPHARMA, INC.
Filing Type: Form 8-K (Current Report)
Date of Report: June 5, 2025
Reporting Period: Event-based (June 5, 2025)
On June 5, 2025, Aytu BioPharma, Inc. entered into an Exclusive Commercialization Agreement with Fabre-Kramer Holdings, Inc. to acquire rights to commercialize EXXUA® (gepirone) extended release tablets in the United States. EXXUA is an FDA-approved, first-in-class treatment for Major Depressive Disorder (MDD). The Company anticipates launching the product in the fourth calendar quarter of 2025.
Key Financial Metrics and Transaction Terms
This filing details a material definitive agreement rather than periodic financial results. Key financial terms of the agreement include:
- Upfront Payment: $3,000,000 cash paid on the effective date.
- Second Payment: $3,000,000 due within 45 days of the one-year anniversary of the first physical sale. This increases to $5,000,000 if first-year net sales meet or exceed $35 million.
- Sales Milestones: Payments ranging from $5,000,000 to over $100,000,000 per year based on net sales thresholds starting at $100 million. An additional 10% of net sales exceeding $1 billion is payable.
- Royalties:
- Initial: 28% of net sales (increasing to 39% if net sales exceed $300 million annually).
- Post-Trigger: 24.5% of net sales (increasing to 35.5% if net sales exceed $300 million annually).
- Supply Price: 3% of net sales less cost of goods sold (increasing to 4% if annual net sales exceed $300 million).
Note: The filing does not provide current revenue, profit, cash flow, margins, debt, or liquidity figures for the Company.
Material Changes and Outlook
Material Change: The Company has expanded its commercial portfolio by acquiring exclusive rights to EXXUA, targeting the over $22 billion U.S. prescription MDD market.
Outlook and Management Commentary:
- Management expects to launch EXXUA in Q4 2025.
- The product addresses unmet needs in treating over 21 million Americans with MDD, offering a differentiated clinical profile compared to existing therapeutics.
- EXXUA has been studied in over 5,000 patients.
Risks and Contingencies:
- Termination: The agreement can be terminated for material default (uncured within 90-120 days), safety withdrawals, FDA indication restrictions, or federal/state pricing controls causing substantial loss of sales.
- Regulatory: Obligations include post-marketing trials and regulatory matters.
Investor Verification Checklist
- Verify the Company's current cash position to confirm ability to fund the $3 million upfront payment and future milestone obligations.
- Review the full text of the Exclusive Commercialization Agreement (to be filed as an exhibit to the 2025 Form 10-K) for detailed definitions of "net sales" and royalty triggers.
- Monitor the Q4 2025 launch timeline for EXXUA to assess the timing of the "first physical sale" trigger for the second payment.
- Assess the competitive landscape of the MDD market and potential pricing controls that could impact the $35 million first-year sales threshold.